FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it will provide a regulatory update in a webcast and conference call at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Monday, December 16, 2019.
Analysts and investors can participate in the conference call by dialing (844) 877-4019 for domestic callers and (602) 563-8495 for international callers using the conference ID# 9628308. The webcast can be accessed live on the Investor Relations page of Mirum’s website, and will be available for replay for 30 days following the call.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.